UHL researchers part of major leukemia study in NEJM
Professor Ruth Clifford and team of the Haematology Department at UHL and their international collaborators have just published a major study in the management of in patients with previously untreated CLL, fixed-duration treatment with venetoclax–obinutuzumab or venetoclax–ibrutinib demonstrating noninferiority to continuous ibrutinib with regard to investigator-assessed progression-free survival.